Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
History
Music
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/c6/df/bb/c6dfbb60-f31a-08bc-fbe5-32a7b9e73259/mza_7348302635350084266.jpg/600x600bb.jpg
Adopting the Evolving Management of HR+/HER2-mBC into Practice
Annenberg Center for Health Sciences
4 episodes
1 day ago
Survival outcomes for patients with HR+/HER2- mBC remain suboptimal, despite first-line treatment strategies with endocrine therapy (ET). Greater understanding of the biology of HR+/HER2- mBC, including the role of biomarkers like ESR1 mutations, and the development of biopsy techniques for early mutation detection, have paved the way for personalized treatment approaches. In this activity, medical oncologists discuss integrating these evidence-based advancements into practice.
Show more...
Medicine
Health & Fitness
RSS
All content for Adopting the Evolving Management of HR+/HER2-mBC into Practice is the property of Annenberg Center for Health Sciences and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Survival outcomes for patients with HR+/HER2- mBC remain suboptimal, despite first-line treatment strategies with endocrine therapy (ET). Greater understanding of the biology of HR+/HER2- mBC, including the role of biomarkers like ESR1 mutations, and the development of biopsy techniques for early mutation detection, have paved the way for personalized treatment approaches. In this activity, medical oncologists discuss integrating these evidence-based advancements into practice.
Show more...
Medicine
Health & Fitness
https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/43430820/43430820-1744128055407-cc0318f647fcd.jpg
Molecular and Tumor Profiling
Adopting the Evolving Management of HR+/HER2-mBC into Practice
22 minutes 54 seconds
7 months ago
Molecular and Tumor Profiling

Molecular and Tumor Profiling

Adopting the Evolving Management of HR+/HER2-mBC into Practice
Survival outcomes for patients with HR+/HER2- mBC remain suboptimal, despite first-line treatment strategies with endocrine therapy (ET). Greater understanding of the biology of HR+/HER2- mBC, including the role of biomarkers like ESR1 mutations, and the development of biopsy techniques for early mutation detection, have paved the way for personalized treatment approaches. In this activity, medical oncologists discuss integrating these evidence-based advancements into practice.